The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Shanthi Rexaline

Wed, May 29, 2019, 7:38 AM

In this article:

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech stocks hitting 52-week highs on May 28)

Adverum Biotechnologies Inc (NASDAQ: ADVM)
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR)
Eidos Therapeutics Inc (NASDAQ: EIDX)
Fate Therapeutics Inc (NASDAQ: FATE)
Insulet Corporation (NASDAQ: PODD)
Milestone Pharmaceuticals Inc (NASDAQ: MIST)

Down In The Dumps

(Biotech stocks hitting 52-week lows on May 28)

Abeona Therapeutics Inc (NASDAQ: ABEO)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Akebia Therapeutics Inc (NASDAQ: AKBA)
Alkermes Plc (NASDAQ: ALKS)
Allena Pharmaceuticals Inc (NASDAQ: ALNA)
ANCHIANO THERAP/S ADR (NASDAQ: ANCN)
Aptinyx Inc (NASDAQ: APTX)
Aquestive Therapeutics Inc (NASDAQ: AQST)
Arbutus Biopharma Corp (NASDAQ: ABUS)
Bellicum Pharmaceuticals Inc (NASDAQ: BLCM)
Cidara Therapeutics Inc (NASDAQ: CDTX)
Endo International PLC (NASDAQ: ENDP)
Harvard Bioscience, Inc. (NASDAQ: HBIO)
Heat Biologics Inc (NASDAQ: HTBX)
Kezar Life Sciences Inc (NASDAQ: KZR)(reacted to negative safety and efficacy data for KZR-616)
Melinta Therapeutics Inc (NASDAQ: MLNT)
Mylan NV (NASDAQ: MYL) (reacted to generic drug lawsuit)
Myriad Genetics, Inc. (NASDAQ: MYGN)
Opko Health Inc. (NASDAQ: OPK)
Seres Therapeutics Inc (NASDAQ: MCRB)
Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH)
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) (reacted to generic drug lawsuit)
Theravance Biopharma Inc (NASDAQ: TBPH)

Stock In Focus Inovio Says AstraZeneca Subsidiary Discontinues Most R&D Collaborations

Inovio Pharmaceuticals Inc (NASDAQ: INO) said in a filing with the SEC it has received notification from AstraZeneca plc (NYSE: AZN)'s MedImmune unit that it intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457.

The two parties will continue to pursue the development of MEDI0457 and AstraZeneca continues to evaluate MEDI0457 in combination with its PD-L1 checkpoint inhibitor durvalumab in multiple Phase 2 trials in patients with cancers associated with HPV.

Inovio's stock fell 16.56 percent to $2.62 in after-hours trading.

Bayer Gets Breakthrough Therapy Designation For Blood Cancer Drug

Bayer AG (OTC: BAYRY) said the FDA has granted Breakthrough Therapy Designation for Aliqopa for the treatment of adult patients with relapsed marginal zone lymphoma, or MZL, who have had at least two prior therapies.

MZL is an indolent form of non-Hodgkin's Lymphoma, accounting for 10 percent of all non-Hodgkin's Lymphoma in the U.S., Bayer said in the release.

Genmab Files For Listing ADSs On Nasdaq

GENMAB A/S/S ADR (OTC: GMXAY), a biotech company listed on the Nasdaq Copenhagen, has filed a registration statement on Form F-1 with the SEC for a proposed listing of its ADSs on the Nasdaq under the ticker symbol GMAB.

Ziopharm Strikes Cell Therapy Collaboration For Cancer

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) announced an exclusive licensing agreement with the National Cancer Institute, or NCI, for intellectual property for the development and commercialization of cell therapies for cancer. The NCI is an institute of the National Institute of Health, or NIH.

The agreement provides for Ziopharm getting rights to two groups of technologies for use with its Sleeping Beauty platform, and the company will in turn will pay the NIH an upfront payment and certain clinical, regulatory, and sales milestone payments, as well as royalties on net sales of products covered by the license.

The stock rallied 6.62 percent to $4.51 in after-hours trading.

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

See more from Benzinga

The IRS says it’s going after wealthy tax cheats. Here’s what new audit stats show.
After Congress approved billions of extra funding for tax compliance, the Internal Revenue Service pledged it would get tougher on rich taxpayers and corporations while avoiding extra scrutiny of middle-class households.
MarketWatch•1h ago
California McDonald's Franchise Owner Says, 'The Focus Is On Survival' With 'Unprecedented' $20 Per Hour Minimum Wage Forcing Higher Prices
In response to California's new $20 minimum wage law, fast food franchises are being forced to rethink their business strategies to stay afloat. Scott Rodrick, who owns 18 McDonald's franchises in the state, is considering measures to manage the increased labor costs without resorting to layoffs, which he sees as a last resort. Don't Miss: 82% of Americans aren’t using this government secured 5% passive income stream, are you one of them? The average American couple has saved this much money for
Benzinga•22h ago
I Was Incredibly Wrong About the Tesla Cybertruck
Unit sales appear considerably below my estimates.
Motley Fool•7h ago
Sam Bankman-Fried Agrees to Help FTX Investors Go After Celeb Promoters
Sam Bankman-Fried has inked a settlement agreement with a group of FTX customers who have agreed to drop their class action lawsuit against him in exchange for his help going after celebrity promoters of the collapsed exchange.
CoinDesk•23h ago
The Bond Market Is Sounding Its Most Severe Alarm in Decades, and It Could Mean Trouble for the Stock Market
This bond market indicator has predicted past recessions with near-perfect accuracy since the mid-1960s, and it's sending Wall Street a warning right now.
Motley Fool•7h ago
Silicon Valley and Hollywood worlds collide as David Ellison bids for Paramount
David Ellison, 41, would not be the first rich guy to arrive in Hollywood with a fat bank account and dreams of making movies, though the son of billionaire Oracle founder Larry Ellison boasts the rarest of attributes for a budding media mogul: a Silicon Valley pedigree. In an industry where many get their start fetching coffee or moving props, Ellison spent summers writing computer code for his father's software company and getting insights on the movie business from Pixar Animation Studios co-founder Steve Jobs. Ellison is orchestrating a multi-step transaction that would result in the merger of his independent studio, Skydance Media, with Paramount.
Reuters•5h ago
Time to Pounce: 2 Phenomenal Ultra-High-Yield REITs That Haven't Been This Cheap in Years
The premier name among retail REITs, along with a 14%-yielding REIT that's returned $25 billion to its shareholders since going public, make for sensational buys right now.
Motley Fool•6h ago
Trump poised to clinch $1.3 billion social media company stock award
Donald Trump is set to secure on Tuesday a stock bonus worth $1.3 billion from the company that operates his social media app Truth Social, equivalent to about half the majority stake he already owns in it, thanks to the wild rally in its shares. The award will take the former U.S. President's overall stake in the company, Trump Media & Technology Group (TMTG), to $4.1 billion. While Trump has agreed not to sell any of his TMTG shares before September, the windfall represents a significant boost to his wealth, which Forbes pegs at $4.7 billion.
Reuters•5h ago
Billionaire Investor David Tepper Has 32% of His Portfolio Invested in These 3 Incredible Artificial Intelligence (AI) Growth Stocks
Do these three AI giants belong in your portfolio, too?
Motley Fool•1h ago
GE Aerospace Surges On Earnings, Outlook After Spinoff
GE stock rallied 5% early Tuesday as GE Aerospace topped quarterly results and raised its operating profit outlook.
Investor's Business Daily•2h ago

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Recommended Stories

The IRS says it’s going after wealthy tax cheats. Here’s what new audit stats show.

California McDonald's Franchise Owner Says, 'The Focus Is On Survival' With 'Unprecedented' $20 Per Hour Minimum Wage Forcing Higher Prices

I Was Incredibly Wrong About the Tesla Cybertruck

Sam Bankman-Fried Agrees to Help FTX Investors Go After Celeb Promoters

The Bond Market Is Sounding Its Most Severe Alarm in Decades, and It Could Mean Trouble for the Stock Market

Silicon Valley and Hollywood worlds collide as David Ellison bids for Paramount

Time to Pounce: 2 Phenomenal Ultra-High-Yield REITs That Haven't Been This Cheap in Years

Trump poised to clinch $1.3 billion social media company stock award

Billionaire Investor David Tepper Has 32% of His Portfolio Invested in These 3 Incredible Artificial Intelligence (AI) Growth Stocks

GE Aerospace Surges On Earnings, Outlook After Spinoff